Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 14/20 | 0.65 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | STAT1 | P42224 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.53 |
| ▸ | ACP1 | P24666 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1308822 | 0.91 | P2RY1 (0.66) | P2RY1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL3160294 | 0.88 | P2RY1 (0.66) | P2RY1NPC1RAB9AP2RY14MAPT | |
| SCHEMBL3145089 | 0.88 | P2RY1 (0.59) | P2RY1NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL3163201 | 0.85 | P2RY1 (0.66) | P2RY1P2RY14 | |
| SCHEMBL3154555 | 0.84 | RAB9A (0.67) | P2RY1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL3155017 | 0.84 | P2RY1 (0.58) | P2RY1NPC1RAB9AP2RY14 | |
| SCHEMBL3155588 | 0.83 | P2RY1 (0.71) | P2RY1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL1307116 | 0.80 | P2RY1 (0.58) | P2RY1 | |
| SCHEMBL3157678 | 0.78 | P2RY1 (0.67) | P2RY1P2RY14 | |
| SCHEMBL1306215 | 0.77 | P2RY1 (0.57) | P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751113-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-10 | — | — | EP | claimed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | claimed |
| EP-1751113-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Bristol-Myers Squibb Pharma Company (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2005113511-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-01 | — | — | WO | claimed |
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | claimed |
| EP-4094762-A1 | TREATMENT OF NEUROLOGICAL INDICATIONS | UCL Business Ltd (GB) | 2022-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY1, P2RY11, P2RY2 | P2RY1 1/4885NPC1 2764/4885RAB9A 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.